Aakash Desai, MD, MPH, FASCO (@ADesaiMD)

Pinned

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 4, 2020

As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife

ADesaiMD's tweet image. As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife

32

53

206

16

0

Aakash Desai, MD, MPH, FASCO Retweeted

L

LungCancerRx 🫁💊@LungCancerRx · Jul 23

Missing our third musketeer here at #BTGLung2025! @ADesaiMD @lungoncdoc @FawziAbuRous

1

3

18

0

913

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 22

New @NatureRevDrugDisc “Analyst’s Couch” on the NSCLC drug market: sales are projected to climb from US$31.7B (2024) to $56.1B by 2032 (Clarivate). NSCLC accounts for ~85% of lung cancers—major unmet needs persist across lines of therapy. Read more: nature.com/articles/d4157…

ADesaiMD's tweet image. New @NatureRevDrugDisc “Analyst’s Couch” on the NSCLC drug market: sales are projected to climb from US$31.7B (2024) to $56.1B by 2032 (Clarivate). NSCLC accounts for ~85% of lung cancers—major unmet needs persist across lines of therapy. Read more: nature.com/articles/d4157…

0

6

24

12

2.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 22

The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation nature.com/articles/d4157… @OncoAlert @LungCancerRx

ADesaiMD's tweet card. Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com

1

4

15

3

1.0K

Aakash Desai, MD, MPH, FASCO Retweeted

P

Paolo Tarantino@PTarantinoMD · Jul 21

Which books do oncologists say their peers should read this summer? Loved to contribute to this project, alongside amazing colleagues! oncologynewscentral.com/experience/boo…

3

14

55

37

12.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 21

‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! @OncoAlert

RRami Manochakian MD, FASCO Cancer Education@RManochakian · Jul 21

🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…

6

16

48

7

7.0K

Aakash Desai, MD, MPH, FASCO Retweeted

B

Balazs Halmos@BalazsHalmosMD · Jul 21

Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide! With OS being the 🐘in the room and both MARIPOSA and FLAURA2 reaching this key endpoint- the pendulum has clearly swung in…

4

13

71

15

7.0K

Aakash Desai, MD, MPH, FASCO Retweeted

d

d.planchard@dplanchard · Jul 21

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer

1

20

75

13

7.0K

Aakash Desai, MD, MPH, FASCO Retweeted

R

Rami Manochakian MD, FASCO Cancer Education@RManochakian · Jul 21

🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…

4

17

60

2

12.0K

Aakash Desai, MD, MPH, FASCO Retweeted

J

Jennifer A. Marks, MD@jennifermarksmd · Jul 17

Will be interesting to see if chair time is truly decreased in actual practice. Fingers crossed the price for SQ doesn’t change. I worry this will be a similar story to Neulasta (and its many formulations) and prior auth issues. Great article!

0

1

3

0

387

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 16

🎉Out now! "Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?" in @JCOOP_ASCO💉 #SC delivery means less chair time for patients & more efficient clinics! But there are financial hurdles we need to tackle. 🔗bit.ly/455GyJQ

ADesaiMD's tweet image. 🎉Out now! "Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?" in @JCOOP_ASCO💉
#SC delivery means less chair time for patients &amp; more efficient clinics! But there are financial hurdles we need to tackle.
🔗bit.ly/455GyJQ

7

19

78

27

8.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 16

Hi friends, it's #LungCancer Wednesday. Here are Top Posts of the Week! 🎉🎉🎉 1/ @ADesaiMD on advancing precision ADC therapy in NSCLC: x.com/ADesaiMD/statu…

AAakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

🚨 Thrilled to share our latest in Experimental Hematology & Oncology: "Advancing #precision ADC therapy in NSCLC" 🧬 Integrated transcriptomic + proteomic profiling ◼️ Defined targetable tumor subtypes ◼️ Strong RNA–protein correlation ◼️ Biomarker-driven ADC stratification

2

5

14

0

1.0K

Aakash Desai, MD, MPH, FASCO Retweeted

K

Katsuaki Maehara 🇯🇵@KatsuakiMaehara · Jul 15

@ADesaiMD @JAMA_current #nsclc #LCSM #immunotherapy 🌟 The paper is here. (Open access) jamanetwork.com/journals/jaman…

0

1

2

5

510

Aakash Desai, MD, MPH, FASCO Retweeted

M

Mario Balsa@MarioBalsaMD · Jul 15

🚨 Just out in @JTOonline! A must-read review from the @IASLC Communications Committee: 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic jto.org/article/S1556-… 🧭 A fast-track tour in #LungCancer, from staging to immunotherapy. Perfect to breathe in the past…

19

28

91

45

10.0K

Aakash Desai, MD, MPH, FASCO Retweeted

J

Jill Feldman@jillfeldman4 · Jul 14

The most important conversations oncs have with patients and families aren't data-driven. #LungCancerRx episode 2 is live bit.ly/450O7l3. We delve into one of the most important (and often overlooked) aspects of #lungcancer care: conversations - not just about…

2

10

32

1

3.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

New study out today uses RNA & protein data to match #LungCancer tumours to personalised ADC treatments, targeting CEA & TACSTD2. For people with NSCLC - esp. those not responding to chemo (20-30% rate, Lancet Oncology 2022) - this could mean effective, tailored therapies, fewer…

AAakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

🚨 Thrilled to share our latest in Experimental Hematology & Oncology: "Advancing #precision ADC therapy in NSCLC" 🧬 Integrated transcriptomic + proteomic profiling ◼️ Defined targetable tumor subtypes ◼️ Strong RNA–protein correlation ◼️ Biomarker-driven ADC stratification

1

3

12

0

1.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

🎙️ Episode 2 of the #LungCancerRx podcast is out now! We dive into shared decision-making and how to empower patients in navigating treatment choices. Featuring @jillfeldman4, @lungoncdoc, @ADesaiMD In collaboration with @EGFRResisters & @OncNewsCentral Listen + subscribe!…

T@ ·

2

3

12

2

1.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

🎙️New #episode for @LungCancerRx just dropped continuing our conversation with @jillfeldman4 @lungoncdoc @FawziAbuRous discussing treatment selection and #shared decision-making! @OncNewsCentral @OncBrothers @EGFRResisters @HemOncFellows @ONealCancerUAB

T@ ·

1

5

13

0

1.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 11

🚨 Thrilled to share our latest in Experimental Hematology & Oncology: "Advancing #precision ADC therapy in NSCLC" 🧬 Integrated transcriptomic + proteomic profiling ◼️ Defined targetable tumor subtypes ◼️ Strong RNA–protein correlation ◼️ Biomarker-driven ADC stratification

ADesaiMD's tweet image. 🚨 Thrilled to share our latest in Experimental Hematology &amp; Oncology: "Advancing #precision ADC therapy in NSCLC"
🧬 Integrated transcriptomic + proteomic profiling
◼️ Defined targetable tumor subtypes
◼️ Strong RNA–protein correlation
◼️ Biomarker-driven ADC stratification

3

6

47

25

8.0K

Aakash Desai, MD, MPH, FASCO Retweeted

H

Hakan Önder@onder_haka2124 · Jul 6

🚨 JAMA 2025 Real world reckoning in resectable NSCLC: • Neoadjuvant IO usage: 13.8% • Adjuvant IO: 22.6% • PD-L1 untested: 47% • EGFR/ALK untested: 50% Treatment exists but testing, selection, and uptake don’t follow. #LCSM #NSCLC @OncoAlert 🔗 jamanetwork.com/journals/jaman…

1

14

57

21

8.0K

A

Aakash Desai, MD, MPH, FASCO@ADesaiMD · Jul 4

Have you caught up on Episode 1 of @LungCancerRx yet? Your refill is almost due… because Episode 2 drops NEXT WEEK! 🎧💥 @OncNewsCentral @lungoncdoc @FawziAbuRous @ADesaiMD @jillfeldman4

OOncology News Central@OncNewsCentral · Jun 13

🎙️NEW PODCAST for Oncology Professionals In our launch episode, hear how #oncologists can work hand-in-hand with advocates to improve outcomes. bit.ly/45VzLTY @lungoncdoc @FawziAbuRous @ADesaiMD @jillfeldman4 @EGFRResisters #LungCancerRx #OncologyPodcast #oncology

0

5

15

0

2.0K